Browse

Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage (WHO label)	Target Gene	Primer Name	Primer Sequence	Primer Length	Primer GC Content (%)	Start Position	End Position	Primer Direction	ΔG (cal)	Primer first used
BA.1.1.15	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BF.7.16	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.2.3.5	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
CQ.1.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
EC.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.5.2.52	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
XBQ	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.5.6.3	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
CR.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BV.2	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
GA.4.1.3	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
GS.7.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
XW	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.1.10	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
JN.8	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
KG.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
XDJ	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
HK.3.8	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
GK.1.7	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
JN.5.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
JN.1.36.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.2.86.4	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
XDF	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.575.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
JN.12	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
GK.10	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
XBB.2.3.10	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.620	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
JN.2.4	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
XDM	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.1.16	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
BA.2.30	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
JN.3.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
LV.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
HK.23	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
GE.1.2.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
V.2	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.149	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.1.413	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.258.4	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.9.5	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.1.107	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.10	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.177.9	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
AY.4.10 (Delta)	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-1668.53	US
B.47	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.36.16	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
AY.41 (Delta)	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
B.1.1.71	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
AS.1	N	US-CDC-N-2	GCGCGACATTCCGAAGAA	18	55.56	29230	29213	R	-21404.2	US
Lineage (WHO label)	Target Gene	Primer Name	Primer Sequence	Primer Length	Primer GC Content (%)	Start Position	End Position	Primer Direction	ΔG (cal)	Primer first used